Helix Energy Solutions
http://www.helixesg.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Helix Energy Solutions
Bold Plans Pivotal GI Cancer Studies After Phase II Success
The private Canadian biotech is advancing a first-in-class GRP78 inhibitor into Phase III studies in gastrointestinal cancers after interim Phase II data suggested potential to improve upon on standard-of-care efficacy.
Finance Watch: Five More Small IPOs Squeeze Through The US Window
Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m.
Medtronic Brings Radial Access Technology To Brain Interventions
The company has begun a limited release of the radial artery access devices it added to its neurovascular therapies business when it quietly acquired RIST Neurovascular in 2020.
Waverley Lists In Frankfurt
Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice